Keyphrases
Aromatase Inhibitors
100%
Drug Choice
100%
Hormonal Therapy
100%
Generic Entry
100%
Pharmaceutical Access
100%
Initiation Rate
22%
Non-initiation
22%
Medicare
11%
Newly Diagnosed
11%
Population-based Study
11%
Initial Treatment
11%
High Prices
11%
Cost Sharing
11%
Hormone Receptor-positive Breast Cancer
11%
Change of Measure
11%
Generic Drugs
11%
Surveillance Epidemiology
11%
Clinical Factors
11%
Delayed Diagnosis
11%
Breast Cancer Drugs
11%
Year of Diagnosis
11%
Estimation Time
11%
Breast Cancer Cases
11%
Price Change
11%
Neoadjuvant Endocrine Therapy
11%
Insurance Coverage
11%
Medication Overuse
11%
Underuse
11%
Time to Initiation
11%
Drug Pricing
11%
Timeliness of Treatment
11%
Recommended Treatment
11%
Policy Debate
11%
Linked Database
11%
Pharmacology, Toxicology and Pharmaceutical Science
Drug Choice
100%
Hormone Cancer Therapy
100%
Aromatase Inhibitor
100%
Breast Cancer
60%
Tamoxifen
40%
Generic Drug
20%
Hormone Receptor
20%
Agricultural and Biological Sciences
Aromatase Inhibitor
100%
Tamoxifen
40%
Sole
20%
Hormone Receptor
20%